Several Circulating Biomarkers for PCOS Diagnosis

Abstract

Aims Irisin, Betatrophin and Zinc-α2-glycoprotein (ZAG) have been shown to be associated with insulin resistance (IR) and polycystic ovary syndrome (PCOS), respectively. The purpose of this study is to explore the potential accuracy of this combination of three cytokines in screening PCOS.

Methods 186 individuals were recruited for this study. Circulating Irisin, Betatrophin and ZAG concentrations were measured by enzyme-linked immunosorbent assay. The association between these serum biomarkers and PCOS was assessed by logistic regression analysis. Receiver operating curve (ROC) analysis was performed to evaluate the diagnostic value of these biomarkers for PCOS women.

Results In women with PCOS, serum Irisin and Betatrophin levels were markedly elevated compared to those in healthy controls (p<0.01), while ZAG levels were lower (p<0.01). PCOS women with IR (M-value<6.28) had lower circulating ZAG concentrations, and higher circulating Irisin and Betatrophin levels relative to PCOS women without IR (M-value ≥ 6.28). ROC curve analyses showed that the AUC for Irisin, ZAG and Betatrophin for predicting PCOS were 0.77, 0.83 and 0.85, respectively. In a joint ROC curves analysis of these serum markers and other parameters, the results showed that the AUC was 0.93, and the sensitivity and specificity were 82.1 % and 92.3 %, respectively.

Conclusions When compared to using single cytokine, the analysis of Irisin, ZAG and Betatrophin elevates the accuracy in diagnosing PCOS.

Key words

biomarker - cytokine - insulin resistance - PCOS

Publication History

Received: 15 July 2019
Received: 04 October 2019

Accepted: 10 October 2019

Article published online:
04 November 2019

• References

• 1 Calan M, Yilmaz O, Kume T. et al. Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. Endocrine 2016; 53: 271-279
• 2 Azziz R, Carmina E, Dewailly D. et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245
• 3 Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236
• 4 Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91: 492-497
• 5 Lewy VD, Danadian K, Witchel SF. et al. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001; 138: 38-44
• 6 Palmert MR, Gordon CM, Kartashov AI. et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 1017-1023
• 7 Tfayli H, Arslanian S. Menstrual health and the metabolic syndrome in adolescents. Ann NY Acad Sci 2008; 1135: 85-94
• 8 Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: Roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 66-71
• 9 Tfayli H, Ulnach JW, Lee S. et al. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: Comparison of metabolic, hormonal, and cardiovascular risk factors. J Clin Endocrinol Metab 2011; 96: 1311-1319
• 10 Yang M, Liu R, Li S. et al. Zinc-alpha2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: Cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 2013; 36: 1074-1082
• 11 Li M, Yang M, Zhou X. et al. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015; 100: 1485-1493
• 12 Wang H, Du L, Wu T. et al. Circulating betatrophin is associated with insulin resistance in humans: cross-sectional and interventional studies in vivo and in vitro. Oncotarget 2017; 8: 96604-96614
• 13 Gomez-Ambrosi J, Pascual E, Catalan V. et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab 2014; 99: E2004-E2009
• 14 Moreno-Navarrete JM, Ortega F, Serrano M. et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769-E778
• 15 Rolli V, Radosavljevic M, Astier V. et al. Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient mice. FEBS Lett 2007; 581: 394-400
• 16 [Anonymous]. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
• 17 Li K, Liao X, Wang K. et al. Myonectin predicts the development of type 2 diabetes. J Clin Endocrinol Metab 2018; 103: 139-147
• 18 Albareda M, Rodriguez-Espinosa J, Murugo M. et al. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000; 43: 1507-1511
• 19 Fang X, Zhang T, Yang M. et al. High circulating alarin levels are associated with presence of metabolic syndrome. Cell Physiol Biochem 2018; 51: 2041-2051
• 20 Rana KS, Pararasa C, Afzal I. et al. Plasma irisin is elevated in type 2 diabetes and is associated with increased E-selectin levels. Cardiovasc Diabetol 2017; 16: 147
• 21 Shanaki M, Moradi N, Emamgholipour S. et al. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab Syndr 2017; 11 (Suppl. 01) S467-s472
• 22 Akour A, Kasabri V, Boulatova N. et al. Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients. Acta Diabetol 2017; 54: 163-170
• 23 Chang CL, Huang SY, Hsu YC. et al. The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Sci Rep 2019; 9: 6447
• 24 Cai X, Qiu S, Li L. et al. Circulating irisin in patients with polycystic ovary syndrome: A meta-analysis. Reprod Biomed Online 2018; 36: 172-180
• 25 Wang W, Guo Y, Zhang X. et al. Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients. Clin Endocrinol (Oxf) 2018; 89: 474-480
• 26 Adamska A, Karczewska-Kupczewska M, Lebkowska A. et al. Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome. Endocr J 2016; 63: 1107-1112
• 27 Lai Y, Chen J, Li L. et al. Circulating Zinc-alpha2-glycoprotein levels and insulin resistance in polycystic ovary syndrome. Sci Rep 2016; 6: 25934
• 28 Zheng S, Liu E, Zhang Y. et al. Circulating zinc-alpha2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment. Endocr J 2019; 66: 555-562
• 29 Varikasuvu SR, Panga JR, Satyanarayana MV. Circulating Angiopoietin-like 8 protein (ANGPTL8/Betatrophin) in patients with polycystic ovary syndrome: A systematic review and multi effect size meta-analysis. Gynecol Endocrinol 2019; 35: 190-197
• 30 Eksi Haydardedeoglu F, Bagir GS, Haydardedeoglu B. et al. Serum betatrophin levels are reduced in patients with full-blown polycystic ovary syndrome. Gynecol Endocrinol 2019; 35: 224-227
• 31 Kahraman S, Altinova AE, Yalcin MM. et al. Association of serum betatrophin with fibroblast growth factor-21 in women with polycystic ovary syndrome. J Endocrinol Invest 2018; 41: 1069-1074
• 32 Adamska A, Lebkowska A, Jacewicz M. et al. Serum concentrations of betatrophin and its association with indirect indices of insulin resistance and beta cell function in women with polycystic ovary syndrome. Int J Endocrinol 2017; 2316986
• 33 Erol O, Ozel MK, Ellidag HY. et al. Assessment of circulating betatrophin concentrations in lean glucose-tolerant women with polycystic ovary syndrome. J Obstet Gynaecol 2017; 37: 633-638
• 34 Erbag G, Eroglu M, Turkon H. et al. Relationship between betatrophin levels and metabolic parameters in patients with polycystic ovary syndrome. Cell Mol Biol (Noisy-le-grand) 2016; 62: 20-24